Jared Weiss, MD, University of North Carolina at Chapel Hill

home / authors / jared-weiss-md-university-of-north-carolina-at-chapel-hill

Articles

Emerging Agents and Future of Small Cell Lung Cancer

Jared Weiss, MD, University of North Carolina at Chapel Hill ;Stephen V. Liu, MD, Georgetown University

April 2nd 2021

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Management of ES-SCLC: Second Line and Beyond

Jared Weiss, MD, University of North Carolina at Chapel Hill ;Stephen V. Liu, MD, Georgetown University

April 2nd 2021

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Using Trilaciclib for Treatment of ES-SCLC

Jared Weiss, MD, University of North Carolina at Chapel Hill ;Stephen V. Liu, MD, Georgetown University

April 2nd 2021

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

Standard of Care for ES-SCLC

Jared Weiss, MD, University of North Carolina at Chapel Hill ;Stephen V. Liu, MD, Georgetown University

March 25th 2021

Experts in thoracic oncology review data from the IMpower133 and CASPIAN trials as well as the use of chemotherapy with PD-L1 inhibitors for treatment-naïve ES-SCLC in clinical practice.

Staging for Small-Cell Lung Cancer

Jared Weiss, MD, University of North Carolina at Chapel Hill ;Stephen V. Liu, MD, Georgetown University

March 25th 2021

Insights on the differences between limited-stage and extensive-stage small-cell lung cancer and recent progress made with combination chemotherapy plus immunotherapy.